Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Buschke-Ollendorff syndrome (BOS) is a benign disorder characterized by the association of osteopoikilosis lesions (``spotted bones'') in the skeleton and connective tissue nevi in the skin.
Features include always present findings: Osteopoikilosis, Epidermal nevus, Nevus, and Sideways curvature of the spine (scoliosis) and others. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 4 | Osteopoikilosis, Sideways curvature of the spine (scoliosis), Joint stiffness |
Muscles | 1 | Flexion contracture |
Arms and legs | 1 | Lower limb asymmetry |
LEMD3 encodes LEM domain containing 3 (911 aa). Can function as a specific repressor of TGF-beta, activin, and BMP signaling through its interaction with the R-SMAD proteins. Antagonizes TGF-beta-induced cell proliferation arrest Highest expression in Brain Cerebellar Hemisphere (28.0 TPM) and Uterus (26.4 TPM).
Buschke-Ollendorff syndrome is associated with mutations in the LEMD3 gene on chromosome 12.
The LEMD3 protein participates in EMD/ TMPO/ LEMD3/ LEMD2, EMD/TMPO/LEMD3/LEMD2:Lamin filaments, and EMD/TMPO/LEMD3/LEMD2:Lamin filaments:BANF1:Chromatin pathways.
LEMD3 is classified as a druggable target with score 0.0.
Genetic testing for LEMD3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for Buschke-Ollendorff syndrome.
5 publications have been identified in PubMed for Buschke-Ollendorff syndrome. Research spans Case Report / Case Series (80%) and Review / Meta-Analysis (20%).
Kato Y (2026). [PMID: 41277804](https://pubmed.ncbi.nlm.nih.gov/41277804/). *The Journal of dermatology*. [Case Report / Case Series]
Savian S (2026). [PMID: 42166119](https://pubmed.ncbi.nlm.nih.gov/42166119/). *Ital J Dermatol Venerol*. [Case Report / Case Series]
Tan Y (2025). [PMID: 40195882](https://pubmed.ncbi.nlm.nih.gov/40195882/). *Acta dermato-venereologica*. [Case Report / Case Series]
Bhattacharyya T (2025). [PMID: 39776616](https://pubmed.ncbi.nlm.nih.gov/39776616/). *JBMR plus*. [Review / Meta-Analysis]
Wenokor G (2025). [PMID: 39945784](https://pubmed.ncbi.nlm.nih.gov/39945784/). *Skeletal radiology*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Oct 3, 2026, 10:55 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Buschke-Ollendorff syndrome